title: Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone.
abstract: At least 30-35% of men with erectile dysfunction (ED) fail to respond to treatment with phosphodiesterase type 5 (PDE-5) inhibitors. Testosterone (T) has effects not only on sexual desire, but also on the anatomical and physiological substrate of erection. This study analysed the effects of T administration to men unsuccessfully treated for ED with PDE-5 inhibitors only. Twenty-nine men aged 36-75 years (mean 59 years) with ED were studied. They suffered from ED for a mean of 2.7 years and had subnormal plasma T levels (total T <3.5 ng ml(-1) ). They received parenteral testosterone undecanoate for 102 weeks. Changes of the domains of the International Index of Erectile Function (IIEF) were assessed. After 6 weeks of T treatment, the sexual desire domain of IIEF had improved (from 4.1 ± 1.4 to 7.2 ± 1.7) and erectile function as measured by IIEF started to improve, reaching a plateau after 30 weeks (from 9.1 ± 2.1 to 26.5 ± 2.3). Features of the metabolic syndrome also improved. There were no adverse effects of T administration. Addition of T to treatment of hypogonadal men unsuccessfully treated with PDE-5 inhibitors only, appeared useful and acceptably safe.
authors.affiliation: Department Urology, Instituto Docente de Urología, Valencia, Venezuela. joseantoniogarcia10@hotmail.com
authors.forename: J A
authors.initials: JA
authors.lastname: Garcia
authors.forename: P E
authors.initials: PE
authors.lastname: Sanchez
authors.forename: C
authors.initials: C
authors.lastname: Fraile
authors.forename: P
authors.initials: P
authors.lastname: Escovar
mesh_terms: D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007006:Hypogonadism / Q000150:complications* / Q000503:physiopathology; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000503:physiopathology; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D013739:Testosterone; C010792:testosterone undecanoate